Biogen deals the tau pipeline another blow
The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
A broader use for Regeneron’s Covid-19 antibody combo
Casirivimab plus imdevimab could at last add a hospitalised Covid-19 patient treatment string to their bow.
Clearside’s long-acting eye project shows promise
But data are early, and other groups are also developing less frequent injections for wet AMD.
Sage depressed by Waterfall
The data were statistically significant, but the market had been hoping for more.
Nightstar becomes nightmare, but Biogen has bigger fish to fry
A second clinical failure means that Biogen threw away $877m, but this sum will today be seen as little more than a rounding error.
Novavax's Prevent-19 lives up to its name
But with many Western markets already saturated, it is worth wondering how important Novavax’s Covid-19 jab will become.
Vertex clears the way for Arrowhead
As Arrowhead prepares to unveil key data in alpha-1 antitrypsin deficiency, its life is made easier by Vertex’s second failure in the disease.
Aclaris’s second crack at a topical Jak
But, with Incyte close to market and several big players moving forward, Aclaris’s project will need to stand out from the pack.
